CoChat

ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine

Bhagwat, Shripad V., McMillen, William T., Cai, Shufen, Zhao, Baohui, Whitesell, Matthew, Shen, Weihua, Kindler, Lisa, Flack, Robert S., Wu, Wenjuan, Anderson, Bryan, Zhai, Yan, Yuan, Xiu-Juan, Pogue, Meghann, Van Horn, Robert D., Rao, Xi, McCann, Denis, Dropsey, Andrew J., Manro, Jason, Walgren, Jennie, Yuen, Eunice, Rodriguez, Michael J., Plowman, Gregory D., Tiu, Ramon V., Joseph, Sajan, Peng, Sheng-Bin · 2020 · Molecular Cancer Therapeutics
Cited by 107

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

The ERK pathway is critical in oncogenesis; aberrations in components of this pathway are common in approximately 30% of human cancers. ERK1/2 (ERK) regulates cell proliferation, differentiation, and survival and is the terminal node of the pathway. BRAF- and MEK-targeted therapies are effective in BRAF V600E/K metastatic melanoma and lung cancers; however, responses are short-lived due to emergence of resistance. Reactivation of ERK signaling is central to the mechanisms of acquired resistance. Therefore, ERK inhibition provides an opportunity to overcome resistance and leads to improved efficacy. In addition, KRAS-mutant cancers remain an unmet medical need in which ERK inhibitors may provide treatment options alone or in combination with other agents. Here, we report identification and activity of LY3214996, a potent, selective, ATP-competitive ERK inhibitor. LY3214996 treatment inhibited the pharmacodynamic biomarker, phospho-p90RSK1, in cells and tumors, and correlated with LY3214996 exposures and antitumor activities. In in vitro cell proliferation assays, sensitivity to LY3214996 correlated with ERK pathway aberrations. LY3214996 showed dose-dependent tumor growth inhibition and regression in xenograft models harboring ERK pathway alterations. Importantly, more than 50% target inhibition for up to 8 to 16 hours was sufficient for significant tumor growth inhibition as single agent in BRAF- and KRAS-mutant models. LY3214996 also exhibited synergistic combination benefit with a pan-RAF inhibitor in a KRAS-mutant colorectal cancer xenograft model. Furthermore, LY3214996 demonstrated antitumor activity in BRAF-mutant models with acquired resistance in vitro and in vivo. Based on these preclinical data, LY3214996 has advanced to an ongoing phase I clinical trial (NCT02857270).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-19-0183

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 107

Metadata

Authors
Bhagwat, S. V., McMillen, W. T., Cai, S., Zhao, B., Whitesell, M., Shen, W., Kindler, L., Flack, R. S., Wu, W., Anderson, B., Zhai, Y., Yuan, X.-J., Pogue, M., Van Horn, R. D., Rao, X., McCann, D., Dropsey, A. J., Manro, J., Walgren, J., Yuen, E., Rodriguez, M. J., Plowman, G. D., Tiu, R. V., Joseph, S., & Peng, S.-B.
Venue
Molecular Cancer Therapeutics
Published
2020-02-01
Volume
19
Issue
2
Pages
325-336
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2990581152
Cited by
107
References
10
FWCI
3.51
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine. https://app.cochat.ai/papers/10.1158/1535-7163.mct-19-0183
The paper
Bhagwat, S. V., McMillen, W. T., Cai, S., Zhao, B., Whitesell, M., Shen, W., Kindler, L., Flack, R. S., Wu, W., Anderson, B., Zhai, Y., Yuan, X.-J., Pogue, M., Van Horn, R. D., Rao, X., McCann, D., Dropsey, A. J., Manro, J., Walgren, J., . . . Peng, S.-B. (2020). ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-19-0183

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.